Migraine: CGRP-mAb class switch beneficial among nonresponders or those experiencing gradual loss of efficacyMay 18, 2023Headache & Migraine
Galcanezumab shows sustained response in episodic, chronic, and treatment-resistant migraineMay 18, 2023Headache & Migraine
Eptinezumab lowers monthly migraine days in patients with multiple treatment failuresMay 18, 2023Headache & Migraine
Commentary: Migraine and the relationship to gynecologic conditions, May 2023May 3, 2023Headache & Migraine
Atogepant prevents episodic migraine in some difficult-to-treat casesApril 26, 2023Headache & Migraine
Fremanezumab shows early and sustained efficacy in patients with multiple migraine treatment failuresApril 18, 2023Headache & Migraine
